Company Overview
Inogen, Inc. operates as a medical technology company dedicated to the development, manufacturing, and marketing of respiratory health products across the United States and international markets. The firm specializes in portable oxygen concentrators designed to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. This entity functions within the Healthcare sector, specifically the Medical Devices industry, which encompasses the creation of essential equipment for patient care and life support. The company holds a market capitalization of $174.83M and reported annual revenue of $348.67M over the trailing twelve months. With an employee count of 753, these valuation and revenue figures suggest that Inogen operates as a mid-sized player in the specialized medical device landscape. The relatively modest market cap relative to its revenue stream indicates a company that is likely focused on niche market penetration rather than broad-scale dominance, while the revenue scale demonstrates an established presence in the respiratory therapy supply chain.
Financial Health
The company generated revenue of $348.67M, recorded a net income of $-22,747,000, and reported EBITDA of $-9,548,000 during the trailing twelve months. The significant disparity between the positive revenue of $348.67M and the negative net income reveals a cost structure where operating expenses and losses substantially outweigh gross profits. Free cash flow stands at $-21,157,376, indicating that the company is currently burning cash, which limits its immediate financial flexibility for capital expenditures or aggressive expansion without external financing. Despite the negative earnings, the company maintains a cash balance of $119.58M against total debt of $17.48M, resulting in a debt-to-equity ratio of 9.09. This comparison shows that while the company is leveraged, the substantial cash reserve provides a buffer against its short-term debt obligations. Liquidity is supported by a current ratio of 3.12, which indicates that the company possesses more than three times the current assets necessary to cover its short-term liabilities. Return on Equity is -12.4% and Return on Assets is -6.3%, metrics that reveal that management is currently generating negative returns on the capital invested in the business. These negative return figures suggest that the company is not yet profitable on a per-share or per-asset basis, reflecting the high costs associated with research, development, or sales initiatives in the medical device sector.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the negative net income, while the forward P/E is -20.71. The absence of a positive trailing P/E implies that traditional earnings-based valuation models are not applicable, whereas the negative forward P/E suggests that the market is pricing in expectations of continued losses or a significant turnaround required before profitability is realized. The price-to-book ratio is 0.91, indicating that the market values the company at 91% of its book value, which suggests no market premium over the net asset value and potentially a perception of undervaluation or high risk. Alternative valuation metrics such as the price-to-sales ratio of 0.50 and an EV/EBITDA of -7.62 provide further context, showing that the market is willing to pay half of the sales revenue for the company's equity. The 52-week high is $9.13 and the 52-week low is $5.34. Without the current price explicitly stated in the provided facts, the range defines the historical volatility within which the stock has traded, with the forward P/E implying the stock price may be trading at a level that reflects these earnings expectations. The beta value is 1.78, which signifies that the stock exhibits significantly higher price volatility relative to the broader market, moving with an intensity nearly double that of a standard market index.
Growth & Income
Revenue growth year-over-year is 2.0%, while earnings growth year-over-year is N/A due to the lack of comparable positive earnings data. The fact that revenue is growing at a positive 2.0% rate while earnings remain negative implies that top-line expansion is occurring without yet translating into bottom-line profitability, a common characteristic in capital-intensive medical device firms. Regarding income, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. Because the payout ratio is 0.0% and the net income is negative, the company is not paying dividends but is instead retaining all available cash to fund operations, research, and potential future growth initiatives. The overall growth and income profile presents a scenario of modest revenue expansion coupled with a complete reinvestment of earnings back into the business rather than income distribution to investors.